SCHEMBL19995528

SCHEMBL19995528

CC(C)(C)OC(=O)N1C[C@@H](c2cc(F)cc(F)c2)C[C@H]1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
DPP4 P27487 1/20 0.37
HTRA1 Q92743 1/20 0.37
TACR1 P25103 3/20 0.37
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
NR1H2 P55055 5/20 0.36
NR1H3 Q13133 4/20 0.36
RIPK1 Q13546 1/20 0.36
HSD11B1 P28845 1/20 0.36
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
USP30 Q70CQ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21527811 1.00 CYP1A2 (0.38) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL21136402 1.00 CYP1A2 (0.38) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL23454767 1.00 CYP1A2 (0.38) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL20002178 1.00 CYP1A2 (0.38) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL19995556 0.84 HTRA1 (0.44) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL19995593 0.84 HTRA1 (0.44) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL19995596 0.84 HTRA1 (0.44) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL19995555 0.84 HTRA1 (0.44) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL21527903 0.83 DPP4 (0.40) CYP1A2POLBCYP3A4CYP2C19DPP4
SCHEMBL20005725 0.83 DPP4 (0.40) CYP1A2POLBCYP3A4CYP2C19DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2022-01-20 US disclosed
US-11034695-B2 Dopamine-β-hydroxylase inhibitors BIAL—Portela & Cᵃ, S.A. (PT) 2021-06-15 US disclosed
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors BIAL—PORTELA & CA, S.A. (PT) 2021-04-13 US disclosed
US-20200181148-A1 DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL-PORTELA & CA, S.A. (PT) 2020-06-11 US disclosed
US-20190337950-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL-PORTELA & CA, S.A. (PT) 2019-11-07 US disclosed
EP-3515433-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2019-07-31 EP disclosed
WO-2018056854-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS DBH, SLC6A3, SLC6A2 CYP1A2 147/4885POLB 678/4885CYP3A4 265/4885
US-20190337950-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS DBH, SLC6A3, SLC6A2 CYP1A2 136/4885POLB 633/4885CYP3A4 283/4885
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors DBH, SLC6A3, SLC6A2 CYP1A2 145/4885POLB 710/4885CYP3A4 293/4885
US-20200181148-A1 DOPAMINE-B-HYDROXYLASE INHIBITORS DBH, MAOB, SLC6A3 CYP1A2 146/4885POLB 620/4885CYP3A4 360/4885
US-11034695-B2 Dopamine-β-hydroxylase inhibitors DBH, SLC6A3, COMT CYP1A2 174/4885POLB 774/4885CYP3A4 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.